Biosyent Inc. (RX) - Total Assets
Based on the latest financial reports, Biosyent Inc. (RX) holds total assets worth CA$47.79 Million CAD (≈ $34.57 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Biosyent Inc. investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Biosyent Inc. - Total Assets Trend (1997–2024)
This chart illustrates how Biosyent Inc.'s total assets have evolved over time, based on quarterly financial data. Explore RX long-term investment intensity to see how much of total assets are deployed in long-term investments.
Biosyent Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Biosyent Inc.'s total assets of CA$47.79 Million consist of 59.2% current assets and 40.8% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 29.3% |
| Accounts Receivable | CA$2.39 Million | 5.8% |
| Inventory | CA$5.33 Million | 12.9% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$5.04 Million | 12.2% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (1997–2024)
This chart illustrates how Biosyent Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Biosyent Inc. worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biosyent Inc.'s current assets represent 59.2% of total assets in 2024, an increase from 36.4% in 1997.
- Cash Position: Cash and equivalents constituted 29.3% of total assets in 2024, up from 9.1% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, a decrease from 27.0% in 1997.
- Asset Diversification: The largest asset category is inventory at 12.9% of total assets.
Biosyent Inc. Competitors by Total Assets
Key competitors of Biosyent Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Biosyent Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.06 | 3.92 | 5.79 |
| Quick Ratio | 4.23 | 3.11 | 5.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$28.86 Million | CA$20.52 Million | CA$24.64 Million |
Biosyent Inc. - Advanced Valuation Insights
This section examines the relationship between Biosyent Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.40 |
| Latest Market Cap to Assets Ratio | 2.76 |
| Asset Growth Rate (YoY) | -0.4% |
| Total Assets | CA$41.36 Million |
| Market Capitalization | $114.06 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Biosyent Inc.'s assets at a significant premium (2.76x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Biosyent Inc.'s assets decreased by 0.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Biosyent Inc. (1997–2024)
The table below shows the annual total assets of Biosyent Inc. from 1997 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$41.36 Million ≈ $29.92 Million |
-0.41% |
| 2023-12-31 | CA$41.53 Million ≈ $30.04 Million |
+2.58% |
| 2022-12-31 | CA$40.49 Million ≈ $29.29 Million |
+8.93% |
| 2021-12-31 | CA$37.17 Million ≈ $26.89 Million |
+10.71% |
| 2020-12-31 | CA$33.57 Million ≈ $24.28 Million |
+8.42% |
| 2019-12-31 | CA$30.97 Million ≈ $22.40 Million |
-0.72% |
| 2018-12-31 | CA$31.19 Million ≈ $22.56 Million |
+24.23% |
| 2017-12-31 | CA$25.10 Million ≈ $18.16 Million |
+30.43% |
| 2016-12-31 | CA$19.25 Million ≈ $13.92 Million |
+31.76% |
| 2015-12-31 | CA$14.61 Million ≈ $10.57 Million |
+37.23% |
| 2014-12-31 | CA$10.64 Million ≈ $7.70 Million |
+74.75% |
| 2013-12-31 | CA$6.09 Million ≈ $4.41 Million |
+66.76% |
| 2012-12-31 | CA$3.65 Million ≈ $2.64 Million |
+130.47% |
| 2011-12-31 | CA$1.58 Million ≈ $1.15 Million |
+70.94% |
| 2010-12-31 | CA$927.19K ≈ $670.72K |
+24.00% |
| 2009-12-31 | CA$747.73K ≈ $540.89K |
-34.20% |
| 2008-12-31 | CA$1.14 Million ≈ $822.09K |
-13.15% |
| 2007-12-31 | CA$1.31 Million ≈ $946.59K |
-10.04% |
| 2006-12-31 | CA$1.45 Million ≈ $1.05 Million |
+41.95% |
| 2005-12-31 | CA$1.02 Million ≈ $741.28K |
+65.57% |
| 2004-12-31 | CA$618.92K ≈ $447.72K |
-19.97% |
| 2003-12-31 | CA$773.39K ≈ $559.46K |
+6.53% |
| 2002-12-31 | CA$725.95K ≈ $525.14K |
-67.86% |
| 2001-12-31 | CA$2.26 Million ≈ $1.63 Million |
+92.31% |
| 2000-12-31 | CA$1.17 Million ≈ $849.62K |
-16.11% |
| 1999-12-31 | CA$1.40 Million ≈ $1.01 Million |
-12.50% |
| 1998-12-31 | CA$1.60 Million ≈ $1.16 Million |
+45.45% |
| 1997-12-31 | CA$1.10 Million ≈ $795.72K |
-- |
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form produc… Read more